News 
Market Data 
Discover
Replies to post #190079 on Anavex Life Sciences Corp (AVXL)
04/20/19 8:43 PM
My point is that there is no "normal" process in the EU at this time. Where did you get your 2% figure? The fact is that if 2-73 is a significant improvement over L-dopa for Parkinson's it will go through the regulatory process in an expedited manner.
Dr. Angela Cenci-Nilsson was Dr. Veronica Francardo's PHD sponsor.
Quote:
"L-dopa…waiting for the next act" with Dr. Angela Cenci-Nilsson
Published on Published onFebruary 8, 2016
Elizabeth (Eli) Pollard
Executive Director at World Parkinson Coalition
19 articles
Why has it taken over 50 years to improve the delivery systems of L-dopa and what can people with Parkinson's expect in the near future? Dr. Angela Cenci-Nilsson of Lund University and who sits on the WPC 2016 Steering Committee, is this month's special guest on the Portland Countdown podcast program. She talks about "L-dopa … waiting for the next act" with Jon Palfreman and Dave Iverson.
I often hear people talk about how ridiculous it is that l-dopa is still the golden drug of choice for addressing Parkinson's symptoms. People want more treatment options, but those who use l-dopa and get good results, could't live without this "old" drug. Isn't it possible to have researchers keep fine tuning the drugs on the market, while others keep searching for new treatments? Dave says in the podcast that refining drugs is not sexy or that lucrative for pharma, but he and Jon agree that refining some of these old drugs, like levodopa is crucial to improving the lives of PwP.
Should people with Parkinson's become more involved in the research process and move from advocates to activists in order to influence funding decisions? PD activists might have more success influencing researchers and companies to do some of the research they may not be that eager to take on, such as the refining of drugs already on the market.
I often hear that PwP are too nice, and that if they want to get more done, they need to take a page out of the AIDS activists' book and get more aggressive in order to push for more changes in treatment options or to refine the drugs that are already on the market.
Is now the time to get more aggressive? If you could dictate PD research right now, starting immediately, what would you ask researchers to focus on?
I have no idea what is going on with this post. Mike is showing that Veronica Francardo, PhD will be presenting a poster at this year's MJFF Parkinson's Disease Therapeutics Conference this Oct. 30.
The grant was given to Nilsson, which really goes to the lab she oversees at Lund.
http://www.lunduniversity.lu.se/lucat/group/v1000356
Francardo most likely specializes in this type of research so Nilsson co-authors the paper with her as per the poster at the World Parkinson Congress 2016.
http://www.anavex.com/investigating-the-potential-neurorestorative-effects-of-a-clinical-sigma-1-receptor-agonist-in-a-mouse-model-of-parkinsons-disease/
Francardo is the lead author of the poster with Nilsson part of it as well and it shows that research was supported by the MJFF. And yes, MJFF is a partner with the World Parkinson Coalition that organizes that conference so I don't believe that Francardo will be presenting the exact same piece she did then.
These two have co-authored many papers over the years as well so I don't accept your assertion that because Francardo is presenting that it has nothing to do with MJFF grant given to Anavex and Nilsson.
http://portal.research.lu.se/portal/en/persons/veronica-francardo(9c206658-28b7-4a7c-a4e3-2f199ca7618a)/publications.html
I'm still waiting for your rebuttal as to IND's don't include trial design BTW.
polarbear77 Tuesday, 08/22/17 05:56:30 PM
Re: plexrec post# 116645 0
Post #
116646
of 190090
The Anavex train indeed Plex. Looks like they could be on track as well for Parkinson's trial readout in advance of Dr Francardo's presentation in May 2018 regarding a2-73 Parkinson's results.
Found her statements below to be fairly definitive and unambiguous re her testing to date. It seems the MJFF grant funds are being put to good use here.
GLTAL
Excerpted below from Dr Francardo [who is an independent researcher with grant funds from the Michael J. Foundation and has been studying the sigma-1 receptor for many years and publishing on the topic since at least 2011 (thanks again for pointing that out OFP)]:
"Using the same animal model of PD as in our previous study (i.e. intrastriatal 6-OHDA mouse model), we investigated the potential neurorestorative effects of ANAVEX 2-73, a compound with activity at both Sigma-1 and muscarinic receptors that is currently being tested in people affected by Alzheimer´s disease. Our results reveal that ANAVEX 2-73 is able to ameliorate parkinsonian motor symptoms in tests assessing spontaneous rotational activity and forelimb use asymmetry, and exerts neuroprotective/neurorestorative effects on the nigrostriatal dopamine system."
https://www.michaeljfox.org/foundation/researchers.php?id=1841
Veronica Francardo, PhD
Assistant Professor, Department of Experimental Medical Science BMC F11 at Lund University
Location: Lund, Sweden
Veronica Francardo received her undergraduate training at the University of Trieste, Italy, where she graduated in Medical Biotechnologies. Since 2007, Veronica is a researcher at Lund University, Sweden, where she obtained her PhD degree in Neurobiology under the supervision of Prof Angela Cenci-Nilsson. Veronica Francardo is currently Assistant Professor in the group of Prof. Angela Cenci-Nilsson and carries out pre-clinical research on animal models of Parkinson’s disease and post-mortem human brain tissue. The main interest of her work is to test and develop potential new therapies for Parkinson’s disease and related disorders."
AI
